https://www.youtube.com/embed/we_t8hlzXW8

GSK launches Panadol and Scotts for children

GlaxoSmithKline Consumer Nigeria Plc (GSK), in line with its aim to do more, feel better and live longer, has launched its Panadol Children’s suspension and Scott’s Cod Liver Oil Emulsion for kids to healthcare professionals (HCPs) at an event held recently in Lagos.

Those in attendance at the event included HCPs from different focus areas (paediatricians, general practitioners, nurses, pharmacists and other health workers).

Speaking at the Launch, , President, African Paediatric Association & Societies, Dr Dorothy Esangbedo emphasized the role of several of GSK products which include; Omega-3 fatty acids, Vitamin A and D and Calcium in the growth and development of children.

A Consultant Neonatologist at the National Hospital Abuja, Dr. Muktar Yola who spoke on the management of pain and fever in children, highlighted the role of children’s paracetamol suspension.

The Marketing Director of GSK Consumer Nigeria Plc, Kerry Alexander, said: ‘Panadol Children’s Suspension provides fast and effective relief for pain and fever in children and is gentle on tiny tummies’.

She added: ‘Scott’s Emulsion, which comes in orange flavour, provides nutrients that contribute to growth and development, normal brain function and the maintenance of a healthy immune system in children. Because Scotts is an emulsion, it has a higher absorption and provides better results than other cod liver products in oil form’.

In a statement issued by the management of the healthcare company which was signed by the Senior Brand Manager, Panadol, Dr Davis Iyoha,it stated that the suspension is suitable for children aged 3 months to 12 years and comes in a bottle with a child-resistant cap for added safety.
Share on Google Plus

About Brandinfo

BrandInfo is an online newspaper that has been specially packaged to dish out exclusive, robust and current information about brands. For inquiries, please call +234 708 967 2875
    Blogger Comment
    Facebook Comment

0 comments:

Post a Comment